Christian Nitsche

#ESC2025 Check out this new meta-analysis that harmonizes data from all phase-3 trials assessing disease-specific Rx in ATTR-CM. There were early improvements in biomarkers, QoL & functional capacity, followed by⬇️CV events & ACM with continued treatment.🔗bit.ly/47UH3Z3

Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry tctmd.com/news/dual-appr…

Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Read more in the @EHJ at doi.org/10.1093/eurhea… #AorticValveReplacement #AmyloidosisAwareness @ESCardio @ESC_Journals

🚨Excited to see the results of our transatlantic registry published in #EHJ. In dual aortic stenosis and ATTR-CM: treat the valve AND the myocardium. AVR and ATTR-specific medication ↓ mortality. doi.org/10.1093/eurhea… #CardioTwitter @ESC_Journals

3/3_🧠 Implication: Dual pathology (AS + ATTR-CA) should not preclude intervention. Combined AVR and disease-modifying therapy may restore prognosis. Non-randomised, but compelling signal for integrated treatment. @EurHeartJ #TAVR #Amyloidosis @JoaoCavalcante @Marco_Merlo

2/3_👥 N=226 (mean age 85) 🔹 71% had AVR (mostly TAVI) 🔹 32% received tafamidis 🔍 Results: Both AVR and tafamidis independently ↓ mortality Dual therapy (AVR + tafamidis) = best outcomes Survival similar to patients with lone AS undergoing AVR #EHJ #ValveDisease @MdNitsche

#JACCINT is proud to honor Dr. Christian Nitsche w/ the Spencer King Award for Outstanding Scholarship for his groundbreaking research on managing fluid overload in pts w/ severe AS (EASE-TAVR)! 🎉 📎: jacc.org/doi/10.1016/j.… #ACC25 #TheFaceOfCardiology #TAVR #vhdAS @MdNitsche

EASE-TAVR RCT: Targeted Management of Fluid Overload in Patients With Severe Aortic Stenosis Undergoing TAVR ✅️ improves clinical outcomes ✅️ improves quality of life #Cardiology #Valve @JACCJournals @a_kammerlander @pe_bartko @heitzin

Expansion of the NAC staging system to detect early mortality in ATTR-CM🫀 Important for: 🔬clinical trial inclusion criteria 💊potential intensified treatment @dr_a_ioannou @dr_m_fontana onlinelibrary.wiley.com/doi/10.1002/ej…

Presented at #ACC2024 and #SimPub in @JACCJournals NT-proBNP progression and ODI detect disease progression and are associated with an increased risk of mortality in cardiac ATTR amyloidosis jacc.org/doi/10.1016/j.…

Multiorgan blood biomarker abnormalities are common and associated with mortality in ATTR-CA. #AHAJournals @dr_a_ioannou ahajrnls.org/3wrNr9A

@DrAndrewLin @MedUni_Wien @KardiologieWien @CardiacimagingB @LancetDigitalH Many thanks, Andrew!

@MdNitsche @MedUni_Wien @KardiologieWien @CardiacimagingB @LancetDigitalH Fantastic work, congrats Christian!

Delighted to share our work on AI-based detection of cardiac amyloidosis on bone scintigraphy scans. ✅Removes interrater variability ✅Works across all amyloid tracers ✅Predicts outcome @MedUni_Wien @KardiologieWien @CardiacimagingB @LancetDigitalH thelancet.com/journals/landi…

NEW Research: Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac #amyloidosis using #ArtificialIntelligence: a retrospective, international, multicentre, cross-tracer development and validation study. Read it here: buff.ly/3VslXLv

#Cardiacamyloidosis is a serious disease in which abnormal proteins accumulate in the #heart muscle and affect heart function. A team led by #MedUniVienna has now developed an #AI system that can automatically detect cardiac amyloidosis. ➡ bit.ly/3TINI1c @TheLancet

Bioprosthetic valve dysfunction after #TAVI occurs at the same rate across the spectrum of life expectancy and is associated w/ higher mortality in patients w/ short but to not in those w/ the longest life expectancy #AorticStenosis #EHJCVI #Echofirst doi.org/10.1093/ehjci/…

🔴How prevalent is cardiac amyloidosis and which patients should be screened? @MdNitsche @ESC_Journals #CardioEd #Cardiology #amyloidosis

In this short video, Dr. Carolina Donà talks about unveiling cardiac #amyloidosis, its characteristics and outcomes among patients w/ mitral regurgitation undergoing #TEER. 📃 #ESCCongress #JACCINT simpub paper: bit.ly/3pNUXVV #CardioTwitter #ACCIntl #vhdMR

Dual pathology cardiac amyloidosis and mitral regurgitation is frequent and carries worse outcomes following mitral valve repair @amyloidosis @mitral @g_heitzinger @pe_bartko @a_kammerlander @m_koschutnik @JMascherbauer @KardiologieWien AddThis | Home authors.elsevier.com/a/1fdFZ6uPJvmt…

Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis | Circulation: Cardiovascular Imaging ahajournals.org/doi/10.1161/CI…